Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF31907 combination therapy in advanced malignant tumors
NCT06394713Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QLF31907 in cancer, sponsored by Qilu Pharmaceutical. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
QLF31907
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06394713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394713.